Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro / Early erythropoietin use for the prevention of anemia in very low birth weight newborns
Rev. méd. Chile
; 128(12): 1313-7, dic. 2000. tab
Article
en Es
| LILACS
| ID: lil-281989
Biblioteca responsable:
CL1.1
ABSTRACT
Background:
Anemia is common among very low birth weight newborns and requires frequent blood tranfusions. Erythropoietin was been reported to be useful in the prevention of this anemia.Aim:
To asses the benefits of early (before the third week of life) Human recombinant Erythropoietin (r-EPO) administration to reduce the requirement of blood tranfusions in very low birth weight newborns. Patients andmethods:
sixty newborns under 1500g of birthweight were randomly assigned to recive r-EPO (n=29) or placebo (n=31) three times per week, during four weeks. Packed red cell volume and reticulocyte counts were measured weekly. Serum erythropoietin was measured prior to eigth dose. Transfusion requirements were recorded.Results:
r-EPO reduced transfusions from 1.41 ñ 1.1 to 0.69 ñ 1 transfusions/newborns (p<0.001). At the fourth week of treatment, reticulocyte count was 14.8 ñ 7 and 6.4 ñ 4.9 percent in the active treatment group and placebo group respectively (p<0.001).Conclusions:
r-EPO reduces the requrement of transfusions in low birth weight infants
Texto completo:
1
Colección:
01-internacional
Banco de datos:
LILACS
Asunto principal:
Eritropoyetina
/
Enfermedades del Prematuro
/
Anemia Neonatal
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
/
Male
/
Newborn
Idioma:
Es
Revista:
Rev. méd. Chile
Asunto de la revista:
MEDICINA
Año:
2000
Tipo del documento:
Article